期刊文献+

辅助生殖技术并发症诊断及处理共识 被引量:81

A consensus of diagnosis and treatment for complications during assisted reproductive technology
原文传递
导出
摘要 促排卵治疗是辅助生殖技术(ART)的重要内容之一,但其改善临床妊娠率的同时,亦使卵巢过度刺激综合征(OHSS)、多胎妊娠、多部位妊娠等并发症发生几率增高。本文从ART并发症的诊断、治疗及预防等方面进行阐述,结合近年来国内、外相关领域研究进展及临床应用,中华医学会生殖医学分会部分专家对ART并发症的诊断和处理达成共识,以指导规范的临床应用。 Ovarian stimulation is one of the important contents of assisted reproductive technology (ART), the application of which improves the clinical pregnancy rate, but increases the rate of ovarian hyperstimulation syndrome (OHSS), multiple pregnancy and hesterotopic pregnancy. This article elaborated the diagnosis, treatment, and prevention of these complications. Combining the study progress and clinical application of related fields do- mestic and abroad in recent years, some experts of Chinese Medical Association reproductive medicine group reached a consensus in order to guide the standardization of its clinical use.
出处 《生殖与避孕》 CAS CSCD 北大核心 2015年第7期431-439,共9页 Reproduction and Contraception
关键词 辅助生殖技术(ART) 促排卵 卵巢过度刺激综合征(OHSS) 医源性多胎妊娠 多部位妊娠 assisted reproductive technology (ART) ovarian stimulation ovarian hyperstimulation syndrome (OHSS) iatrogenic multiple pregnancies hesterotopic pregnancy
  • 相关文献

参考文献58

  • 1Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syn- drome in women undergoing gonadoWopin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril, 2006, 85 (1):112-20.
  • 2Busso C, M, Garcia-Velasoa JA, etal. The non-ergot derived dopamine agonist quinagolide in pre- vention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-ennm)lled trial. Hum Reprod, 2010, 25(4):995-1004.
  • 3Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2):389-400.
  • 4Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotro- phin-releasing hormone antagonists for assisted reproduc- tive technology. Cochrane Database Syst Rev, 2011(5): CD001750.
  • 5Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperslsulafion syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endoerinol, 2012, 10:32.
  • 6Tsoumpou I, Muglu J, G-elbaya TA, et al. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final ooeyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online, 2009, 19(1):52-8.
  • 7Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe early ovarian hyperstimulation syndrome by re- initiation of CmRH antagonist. Reprod Biomed Online, 2007, 15(4):408-12.
  • 8Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online, 2009, 18( 1): 15-20.
  • 9Wada I, Matson PL, Home G, et al. Is continuation of a gouadotrophin-releasing hormone agonist (CmRHa) necessary for women at risk of developing the ovarian hyper-stimulation syndrome? Hum Reprod, 1992, 7(8): 1090-3.
  • 10Endo T, Hounma H, Hayashi T, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, pre- vents ovarian hyperstimtdation syndrome following elective cryopreservation ofaU pronucleate embryos. Hum Reprod, 2002, 17(10):2548-51.

共引文献2

同被引文献486

引证文献81

二级引证文献235

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部